# David Lockhart

> David J. Lockhart, Ph.D. is President and Chief Scientific Officer of ReCode Therapeutics, a clinical-stage biotech pioneering nonviral lipid nanoparticle (LNP) delivery of mRNA and gene-editing payloads to the lungs for genetic respiratory diseases including cystic fibrosis and primary ciliary dyskinesia. With more than 25 years in drug discovery and genomics — from co-founding Ambit Biosciences to leading science at Amicus Therapeutics — Lockhart brings rare-disease chops and deep genomics expertise to ReCode's SORT LNP platform, which has raised $345M and dosed its first patients in a Phase 1 PCD trial.

- **Role:** President & CSO at ReCode Therapeutics
- **Organizations:** ReCode Therapeutics, Amicus Therapeutics, Ambit Biosciences, Novartis Research Foundation (Genomics Institute), Affymetrix
- **Nationality:** American
- **Education:** Ph.D. in Chemistry, Stanford University, Postdoctoral Fellow, Biology, Whitehead Institute, MIT
- **Known for:** Author of over 80 peer-reviewed scientific articles spanning genomics, kinase technology, pharmacological chaperones, and genetic medicine, Inventor on more than 40 issued U.S. patents related to drug development and genomic technologies, Co-founded Ambit Biosciences, pioneering kinase profiling technology

## Career timeline

- **Early career** — Developer of gene expression profiling using DNA microarrays at Affymetrix
- **Early career** — Director of Genomics at the Novartis Research Foundation Genomics Institute
- **2001-2005** — Co-founder, President & CSO at Ambit Biosciences — developed kinase profiling technology and small molecule kinase inhibitors
- **2006-2013** — Chief Scientific Officer at Amicus Therapeutics — led teams that brought multiple rare disease programs into clinical trials
- **2014-2020** — CEO and President at TranscripTx (predecessor company to ReCode Therapeutics)
- **2020-2022** — CEO and President at ReCode Therapeutics
- **2022-present** — President & Chief Scientific Officer at ReCode Therapeutics

## Achievements

- Author of over 80 peer-reviewed scientific articles spanning genomics, kinase technology, pharmacological chaperones, and genetic medicine
- Inventor on more than 40 issued U.S. patents related to drug development and genomic technologies
- Co-founded Ambit Biosciences, pioneering kinase profiling technology
- Led ReCode Therapeutics to raise $345M total funding including a $260M Series B round
- Oversaw ReCode's first patient dosed in a Phase 1 clinical study for primary ciliary dyskinesia (January 2024)
- Helped develop the SORT LNP platform — a fifth-lipid approach enabling organ-specific targeting to the lungs and spleen, bypassing liver hepatocytes
- Led rare disease drug programs at Amicus Therapeutics into clinical trials

## Latest updates

- **2024-10** — Expanded ReCode's Scientific Advisory Board as the company advances clinical programs
- **2024-01** — ReCode Therapeutics dosed its first patient in a Phase 1 clinical study of its mRNA-based therapy for primary ciliary dyskinesia
- **2023-09** — ReCode raised $50M in additional Series B financing, bringing total Series B to $260M and total funding to $345M

## Links

- Website: https://recodetx.com
- LinkedIn: http://www.linkedin.com/in/david-lockhart-6b9a40209

---

Profile page: https://yespress.io/david-lockhart
Published by YesPress — https://yespress.io
Last updated: 2026-05-13